Search

Your search keyword '"Espérou, H."' showing total 124 results

Search Constraints

Start Over You searched for: Author "Espérou, H." Remove constraint Author: "Espérou, H."
124 results on '"Espérou, H."'

Search Results

1. Immunomodulators for immunocompromised patients hospitalized for COVID-19: a meta-analysis of randomized controlled trials

2. Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in infants: a phase 2, randomised, double-blind, active-controlled trial in Guinea and Sierra Leone

3. Implementation of a centralized pharmacovigilance system in academic pan-European clinical trials: Experience from EU-Response and conect4children consortia

4. Acute Myeloid Leukemia (AML) in Children: Results of the French Trials

5. Effect of systematic tuberculosis detection on mortality in young children with severe pneumonia in countries with high incidence of tuberculosis: a stepped-wedge cluster-randomised trial

11. Autoantibodies against type I IFNs in patients with life-threatening COVID-19

13. A potential graft-versus-leukemia effect after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: results from the French Bone Marrow Transplantation Society

24. Prospective validation of a novel IV busulfan fixed dosing for paediatric patients to improve therapeutic AUC targeting without drug monitoring

30. Antithymocyte Globulins (ATG) As Part Of The Myeloablative Conditioning (MAC) Regimen Can Reduce The Risk Of Severe Graft-Vs.-Host Disease (GVHD) After Allogeneic Stem Cell Transplantation (allo-SCT) From Matched-Unrelated Donors (MUD) [A SFGM-TC Study]

36. Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths

37. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19

41. Cardiac Adverse Events and Remdesivir in Hospitalized Patients With COVID-19: A Post Hoc Safety Analysis of the Randomized DisCoVeRy Trial.

42. Management of pharmacovigilance during the COVID-19 pandemic crisis by the safety department of an academic sponsor: Lessons learnt and challenges from the EU DisCoVeRy clinical trial.

43. Implementation of a centralized pharmacovigilance system in academic pan-European clinical trials: Experience from EU-Response and conect4children consortia.

44. Les essais plateformes.

45. Platform trials.

46. Randomized Trial of Vaccines for Zaire Ebola Virus Disease.

47. The Economic, Medical and Psychosocial Consequences of Whole Genome Sequencing for the Genetic Diagnosis of Patients With Intellectual Disability: The DEFIDIAG Study Protocol.

48. Genome Sequencing for Genetics Diagnosis of Patients With Intellectual Disability: The DEFIDIAG Study.

50. Health crisis: What opportunities for clinical drug research?

Catalog

Books, media, physical & digital resources